Neurocrine Biosciences NBIX
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Neurocrine Biosciences (NBIX) Business Model and Operations Summary
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Key Insights
Neurocrine Biosciences (NBIX) Core Market Data and Business Metrics
Latest Closing Price
$134.19Market Cap
$13.23 BillionTotal Outstanding Shares
98.97 Million SharesTotal Employees
1,800Current Dividend
No dividendIPO Date
May 23, 1996SIC Description
Biological Products, (no Disgnostic Substances)Headquarters
6027 Edgewood Bend Court, San Diego, CA, 92130